e-therapeutics Presents New Data Supporting ETX?312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH
MWN-AI** Summary
e-therapeutics plc has revealed promising preclinical data for its small interfering RNA (siRNA) candidate, ETX-312, highlighting its potential as a differentiated, disease-modifying treatment for metabolic dysfunction-associated steatohepatitis (MASH). This announcement was made in anticipation of the European Association for the Study of the Liver (EASL) Congress, where further details will be presented.
In studies conducted using the Gubra-Amylin NASH diet-induced obese (GAN-DIO) mouse model, ETX-312 showed significant improvements in the NAFLD Activity Score (NAS), achieving notable reductions both as a standalone treatment and in conjunction with existing therapies like GLP-1/GIP receptor agonists. The results indicated that all mice treated with combination therapies experienced at least a two-point reduction in NAS, with some showing improvements of up to five points. Additionally, ETX-312 effectively slowed the progression of liver fibrosis, comparable to control treatments, evidenced by marked reductions in hepatic collagen staining and relevant circulating biomarkers TIMP-1 and PIIINP.
Alan Whitmore, Chief Scientific Officer of e-therapeutics, expressed enthusiasm regarding the findings, stating that this data supports ETX-312’s unique position as a potential therapy for MASH. Currently, ETX-312 is advancing through IND-enabling studies, with a regulatory submission expected by the end of 2025.
ETX-312 utilizes the company’s proprietary GalOmic technology, allowing for potentially quarterly subcutaneous dosing. e-therapeutics is focused on leveraging its computational platforms, including HepNet, to drive drug discovery and development, reinforcing its commitment to addressing unmet medical needs. As the company prepares for clinical trials, ETX-312 is poised to play a significant role in the treatment landscape for MASH.
MWN-AI** Analysis
e-therapeutics plc (ETX) has positioned itself at the forefront of RNAi therapeutics, particularly with its promising candidate ETX-312 for metabolic dysfunction-associated steatohepatitis (MASH). Recent preclinical data presented at the EASL Congress indicated not only improved NAFLD Activity Scores (NAS) in treated mice but also showcased potential comparability with existing therapies like GLP-1/GIP receptor agonists.
From an investment perspective, ETX appears to be undergoing a pivotal moment. The company’s strong preclinical results affirm its differentiated approach using GalOmic siRNA technology, which could lead to significant advancements in treating conditions like MASH, characterized by inflammatory liver disease and fibrosis. The combination therapy’s efficacy highlights ETX-312's potential to be a first-in-class treatment.
The company's commitment to submit a regulatory filing by the end of 2025 also signifies confidence in progressing ETX-312 through the clinical trial phases, mitigating some investment risks associated with biotechnology companies that can often encounter delays. The focus on a quarterly subcutaneous dosing regimen strengthens the attractiveness of ETX-312 as a convenient treatment option, likely improving patient adherence and market acceptance.
Investors should also monitor ETX’s ongoing clinical developments in other therapeutic areas, such as dry macular degeneration and bleeding disorders, which parallel the advancement of ETX-312. This diversified pipeline, built on a robust computational platform (HepNet™), positions ETX competitively against other biotech firms pursuing RNAi strategies.
Given these elements, ETX presents a compelling investment opportunity, especially as the market increasingly acknowledges the potential of innovative RNA interference technologies. A proactive investment strategy may benefit from potential stock price appreciation as clinical data emerges and further milestones are achieved. Investors should consider taking a closer look at ETX, balancing the inherent risks of biotech investments with the promising clinical advancements ahead.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LONDON, May 07, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced it will present new preclinical results on its GalOmic small?interfering RNA (siRNA) candidate ETX?312 for the treatment of metabolic dysfunction?associated steatohepatitis (MASH) at the European Association for the Study of the Liver (EASL) Congress, 7 th -10 th May 2025.
In the leading Gubra?Amylin NASH diet?induced obese (GAN?DIO) mouse model, ETX?312 demonstrated:
- Dramatic improvements in NAFLD Activity Score (NAS) when administered as monotherapy or in combination with a GLP?1/GIP receptor agonist or an FGF?21 analogue. All mice receiving combination therapy achieved ??2?point reductions in NAS, with improvements of up to 5 points observed.
- Slowed fibrosis progression comparable to that achieved with GLP?1/GIP receptor agonist or FGF?21 analogue controls, supported by statistically significant reductions in hepatic collagen staining and in circulating biomarkers TIMP?1 and PIIINP.
“These data add to a growing body of evidence supporting ETX-312 as a differentiated, disease-modifying therapy for MASH,” said Alan Whitmore, Chief Scientific Officer. “We are excited to progress the programme towards the clinic.”
ETX?312 is currently in IND?enabling studies, and the Company remains on track to submit a regulatory submission by the end of 2025.
Presentation Details
Title: ETX-312, a GalOmic siRNA for the treatment of MASH, effectively improves the MASH phenotype of GAN DIO-MASH mice alone or in combination with emerging therapies
Poster Number: FRI-337
Date: 9 th May 2025
About ETX-312
ETX?312 is a GalOmic GalNAc-conjugated small-interfering RNA (GalNAc-siRNA) therapeutic candidate in development to be a safe and effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) with potential for a quarterly subcutaneous dosing regimen. In preclinical studies using the Gubra-Amylin NASH diet-induced obese (GAN?DIO) mouse model, administration of ETX-312 led to reductions in NAFLD Activity Score (NAS), decreased hepatic inflammation, and slowed fibrosis progression, both as a monotherapy and in combination with emerging therapies. ETX-312 is currently progressing through IND-enabling studies, with a regulatory submission planned by the end of 2025.
About e-therapeutics plc
e-therapeutics plc ("ETX") uniquely combines computation and RNAi to discover and develop life-transforming medicines. ETX's proprietary RNAi chemistry platform, GalOmic™, enables generation of specific, potent, and durable siRNA therapeutics for effective silencing of novel gene targets in hepatocytes. The cutting-edge HepNet™ computational platform allows ETX to discover better medicines faster through generation of novel insights and increased automation across all stages of drug development. HepNet™ encompasses an extensive hepatocyte-specific knowledgebase and a suite of advanced AI-driven approaches which enable identification of novel gene targets, rapid target-indication assessment, and predictive in silico siRNA design. The Company has specialist expertise and a robust position in applying computation to biology. Its computational approaches have been extensively validated through generation of data from pipeline programs and successful drug discovery collaborations with biopharma companies, such as Novo Nordisk, Galapagos NV, and iTeos Therapeutics.
Leveraging the combined capabilities of HepNet™ and GalOmic™, ETX is progressing a therapeutic pipeline of highly differentiated RNAi candidates across a variety of therapeutic areas with high unmet need. The Company has generated positive proof-of-concept data on preclinical assets in metabolic dysfunction-associated steatohepatitis (MASH), dry age-related macular degeneration (dry AMD), haemophilia, heart failure, and cardiometabolic disease, further validating its computationally enhanced approach to research and development. ETX is currently progressing its GalOmic™ therapies towards the clinic with its most developed assets, ETX-312 for MASH, ETX-148 for bleeding disorders, and ETX-407 for dry AMD, at the IND-enabling stage.
Press Contact
Investor Relations Contact
FAQ**
How does E-Therapeutics Plc ETXPF plan to differentiate ETX-3from existing therapies for metabolic dysfunction-associated steatohepatitis (MASH) based on the preclinical results presented?
Given the positive preclinical findings for ETX-31what specific milestones should investors watch for leading up to the regulatory submission, expected by the end of 2025, for E-Therapeutics Plc ETXPF?
In terms of safety and efficacy, what are the anticipated advantages of the quarterly subcutaneous dosing regimen for ETX-312 compared to current treatment options for MASH offered by E-Therapeutics Plc ETXPF?
How does the HepNet™ computational platform enhance the drug development process for E-Therapeutics Plc ETXPF, specifically in relation to the discovery of novel gene targets for future RNAi therapies?
**MWN-AI FAQ is based on asking OpenAI questions about E-Therapeutics Plc (OTC: ETXPF).
NASDAQ: ETXPF
ETXPF Trading
100.0% G/L:
$0.13 Last:
30 Volume:
$0 Open:
